CN102014967A - 芘携带肽穿过血脑屏障的用途 - Google Patents

芘携带肽穿过血脑屏障的用途 Download PDF

Info

Publication number
CN102014967A
CN102014967A CN2009801166660A CN200980116666A CN102014967A CN 102014967 A CN102014967 A CN 102014967A CN 2009801166660 A CN2009801166660 A CN 2009801166660A CN 200980116666 A CN200980116666 A CN 200980116666A CN 102014967 A CN102014967 A CN 102014967A
Authority
CN
China
Prior art keywords
peptide
pyrene
conjugate
seq
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801166660A
Other languages
English (en)
Chinese (zh)
Inventor
雷内·韦格尔津
安德鲁·纽伯格
D·罗克珊·杜安
艾伦·鲁道夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adlyfe Inc
Original Assignee
Adlyfe Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlyfe Inc filed Critical Adlyfe Inc
Publication of CN102014967A publication Critical patent/CN102014967A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN2009801166660A 2008-03-21 2009-01-30 芘携带肽穿过血脑屏障的用途 Pending CN102014967A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3863408P 2008-03-21 2008-03-21
US61/038,634 2008-03-21
PCT/US2009/000613 WO2009117041A2 (en) 2008-03-21 2009-01-30 Use of pyrene to carry peptides across the blood brain barrier

Publications (1)

Publication Number Publication Date
CN102014967A true CN102014967A (zh) 2011-04-13

Family

ID=40974375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801166660A Pending CN102014967A (zh) 2008-03-21 2009-01-30 芘携带肽穿过血脑屏障的用途

Country Status (8)

Country Link
US (1) US20090238754A1 (enExample)
EP (1) EP2268314A2 (enExample)
JP (1) JP2011517666A (enExample)
CN (1) CN102014967A (enExample)
AU (1) AU2009226161A1 (enExample)
CA (1) CA2718860A1 (enExample)
MX (1) MX2010010266A (enExample)
WO (1) WO2009117041A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759974A (zh) * 2018-07-25 2020-02-07 中国医学科学院药物研究所 一种磷脂-聚乙二醇-狂犬病毒衍生肽聚合物，其制备方法及应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (en) 2001-05-31 2013-02-27 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
EP2156181B1 (en) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier
MX2011007916A (es) * 2009-01-30 2011-11-18 Adlyfe Inc Péptidos conformacionalmente dinámicos.
US20140328762A1 (en) * 2011-04-06 2014-11-06 Yiyi Zhang Fluorogenic Peptide Probes and Assays
EP2712425A2 (en) 2011-04-27 2014-04-02 Adlyfe, Inc. Ocular detection of amyloid proteins
JP6144673B2 (ja) 2011-06-03 2017-06-07 オフィディオン インコーポレイティド 血液脳関門を通過して輸送するための組成物及び方法
PL230602B1 (pl) 2013-04-04 2018-11-30 Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk Kwas (E)-3-arylo-3-oksoprop-1-enylo-2-fosfonowy i jego pochodne, sposob ich wytwarzania oraz ich zastosowanie
PL223918B1 (pl) 2013-05-28 2016-11-30 Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk 3-Arylo-2-fosforylo podstawione 1-indanony i sposób ich wytwarzania
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors
US10369170B1 (en) 2018-10-09 2019-08-06 Carol J. Buck Methods of treating basal cell carcinoma and glioblastoma
US10568907B1 (en) 2018-10-09 2020-02-25 Carol J. Buck Methods of treating basal cell carcinoma and glioblastoma
IL293545A (en) 2019-12-04 2022-08-01 Univ Leland Stanford Junior Enhancing blood-brain barrier drug transport by targeting endogenous regulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822733A (en) * 1985-05-28 1989-04-18 Amoco Corporation Lifetime-resolved assay procedures
US5260308A (en) * 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5604198A (en) * 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
EP1003539A4 (en) * 1997-08-14 2002-09-11 Univ California AMYLOID beta-FLUORESCENT PEPTIDES AND USE THEREOF
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030162698A1 (en) * 1999-01-27 2003-08-28 Alphonse Galdes Methods and compositions for treating dopaminergic and gaba-nergic disorders
AU2001249795A1 (en) * 2000-04-04 2001-10-15 Mayo Foundation For Medical Education And Research Methods for detecting plaques in vivo
US7311893B2 (en) * 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US7470420B2 (en) * 2000-12-05 2008-12-30 The Regents Of The University Of California Optical determination of glucose utilizing boronic acid adducts
WO2002055547A2 (en) * 2001-01-10 2002-07-18 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Sfrp and peptide motifs that interact with sfrp and methods of their use
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
US7851593B2 (en) * 2002-01-04 2010-12-14 Becton, Dickinson And Company Binding proteins as biosensors
JP2006510722A (ja) * 2002-01-29 2006-03-30 プロテミックス コーポレイション リミティド 細胞障害性タンパク質コンフォーマーの抑制
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US20050009109A1 (en) * 2003-07-08 2005-01-13 Stanford University Fluorophore compounds and their use in biological systems
US20060142227A1 (en) * 2003-10-14 2006-06-29 Itschak Lamensdorf Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier
WO2005076732A2 (en) * 2004-02-17 2005-08-25 Kernel Biopharma Inc. Peptide-pna chimera targeting inducible nitric oxide synthase
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
US7951603B2 (en) * 2005-03-31 2011-05-31 The Noguchi Institute Method of mass spectrometric analysis of saccharides with aldehyde groups using labels containing a pyrene ring and a hydrazide group
US7388747B2 (en) * 2006-04-07 2008-06-17 Inventec Corporation Heat plate fixing structure
EP2156181B1 (en) * 2006-07-28 2015-11-04 Adlyfe, Inc. Peptide probes for diagnostics and therapeutics
US20090274621A1 (en) * 2008-03-21 2009-11-05 Adlyfe, Inc Use of pyrene to carry non-peptide agents across the blood brain barrier

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110759974A (zh) * 2018-07-25 2020-02-07 中国医学科学院药物研究所 一种磷脂-聚乙二醇-狂犬病毒衍生肽聚合物，其制备方法及应用
CN110759974B (zh) * 2018-07-25 2021-11-09 中国医学科学院药物研究所 一种磷脂-聚乙二醇-狂犬病毒衍生肽聚合物，其制备方法及应用

Also Published As

Publication number Publication date
CA2718860A1 (en) 2009-09-24
WO2009117041A3 (en) 2010-01-07
JP2011517666A (ja) 2011-06-16
US20090238754A1 (en) 2009-09-24
MX2010010266A (es) 2010-12-14
EP2268314A2 (en) 2011-01-05
AU2009226161A1 (en) 2009-09-24
WO2009117041A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
US20090238754A1 (en) Use of pyrene to carry peptides across the blood brain barrier
Liu et al. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy
US6821504B2 (en) Detection of alzheimer's amyloid by magnetic resonance imaging
US20090274621A1 (en) Use of pyrene to carry non-peptide agents across the blood brain barrier
Liu et al. ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson’s and Huntington’s diseases
AU2010208181B2 (en) Conformationally dynamic peptides
US20110097267A1 (en) Compositions for imaging pain and stress in vivo
US9795692B2 (en) Ocular detection of amyloid proteins
JP2010502938A (ja) 診断および治療のためのペプチドプローブ
US20120282169A1 (en) Detection and treatment of traumatic brain injury
US11382991B2 (en) Molecular probes for imaging of myelin
CN111182913A (zh) 用于通过多个生物屏障进行有效递送的方法和组合物
US10139419B2 (en) Methods for detecting Aβ oligomers
US7279149B2 (en) Amino acid composition with increased blood brain barrier permeability
Imran et al. Fluorescent Organic Molecules as Diagnostic and Theranostic Tools for Alzheimer’s Disease
US20230037660A1 (en) Methods of treating vascular lesions and malformations
Liu et al. Fluorescent Particles based on AIE for Optical Diagnostics of the Central Nervous System
Feng et al. Tuftsin derivatives of FITC, Tb–DOTA or Gd–DOTA as potential macrophage‐specific imaging biomarkers
Elder et al. Toward the Emergence of Nanoneurosurgery: Part III—Nanomedicine: Targeted Nanotherapy, Nanosurgery and Progress toward the Realization of Nanoneurosurgery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413